tirzepatide another name FDA approves new version of diabetes drug Mounjaro to be sold for weight loss Mounjaro (Tirzepatide) Injection for Weight

Compounded medications may vary in effect from person to person, and outcomes are not guaranteed

The FDA prescribing information lists diarrhea as an adverse reaction occurring in 30% of patients treated with the 2.4 mg injection compared with 16% on placebo in the weight-reduction trials

Conclusion GLP-1 medications have changed the conversation around diabetes and weight management

The UK MHRA has approved semaglutide for weight management and specific cardiovascular indications, but oral GLP-1 pills for obesity have not yet been authorised in the UK

The body can no longer rely on the drug to reduce appetite, slowing the metabolism and causing the hunger hormone to kick back in, causing weight regain